Your browser doesn't support javascript.
loading
When RING finger family proteins meet SARS-CoV-2.
Cai, Chunmei; Tang, Yan-Dong; Zheng, Chunfu.
Afiliação
  • Cai C; Department of School of Medical, Research Center for High Altitude Medicine, Qinghai University, Xining, China; Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province, Xining, China.
  • Tang YD; Department of Immunology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
  • Zheng C; State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin, China.
J Med Virol ; 94(7): 2977-2985, 2022 07.
Article em En | MEDLINE | ID: mdl-35257387
ABSTRACT
The pandemic coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently the most formidable challenge to humankind. Understanding the complicated virus-host interplay is crucial for fighting against viral infection. A growing number of studies point to the critical roles of RING (really interesting new gene) finger (RNF) proteins during SARS-CoV-2 infection. RNF proteins exert direct antiviral activity by targeting genome and envelope glycoproteins of SARS-CoV-2. Additionally, some RNF members serve as potent regulators for antiviral innate immunity and antibody-dependent neutralization of SARS-CoV-2. Notably, SARS-CoV-2 also hijacks the RNF proteins-mediated ubiquitination process to evade host antiviral innate immunity and enhance viral replication. In this mini-review, we discuss the diverse antiviral mechanisms of RNF proteins and viral immune evasion in an RNF proteins-dependent manner. Understanding the crosstalk between RNF proteins and SARS-CoV-2 infection would help design potential novel targets for COVID-19 treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article